FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4366609072> ?p ?o ?g. }

• W4366609072 endingPage "327" @default.
• W4366609072 startingPage "321" @default.
• W4366609072 abstract "Little is known regarding outcomes and optimal therapeutic regimens of infections caused by Klebsiella pneumoniae carbapenemase-producing Klebsiella pneumoniae (KPC-Kp) resistant to ceftazidime/avibactam (CZA) and susceptible to meropenem (MEM). Although susceptible to MEM in vitro, the possibility of developing MEM resistance overtime is a concern. We describe the clinical characteristics of patients with colonization/infection due to KPC variants with a focus on the in vitro activity of fosfomycin (FOS)-containing combinations. Patients with colonization/infection due to a KPC variant were included. Fosfomycin susceptibility was performed by agar dilution method. Synergistic activity of FOS-based combinations was evaluated by gradient strip-agar diffusion method. The emergence of in vitro MEM resistance was also tested. Eleven patients were included: eight with infection [four with ventilator-associated pneumonia and four with bloodstream infections] and three with colonization. Previous therapy with CZA was administered to all patients (with a mean cumulative duration of 23 days). All subjects with infection received meropenem, in monotherapy (n = 4) or with amikacin (n = 2) or fosfomycin (n = 2), and achieved clinical cure. A new CZA-susceptible and MEM-resistant KPC-Kp strain was subsequently isolated in three patients (27.3%). Meropenem/vaborbactam (MVB) showed high in vitro activity, while FOS+MEM combination was synergistic in 40% of cases. In vitro resistance to MEM was observed with maintenance of CZA resistance. Detection of KPC variants may occur within the same patient, especially if CZA has been previously administered. Although clinical success has been obtained with carbapenems, the emergence of MEM resistance is a concern. Fosfomycin plus meropenem is synergistic and may be a valuable combination option for KPC variants, while MVB may be considered in monotherapy. The detection of KPC variants in an endemic setting for KPC-Kp represents a worryingly emerging condition. The optimal therapeutic approach is still unknown and the development of meropenem resistance is of concern, which may lead to therapeutic failure in clinical practice. In these cases, the addition of fosfomycin to meropenem, or a more potent antibiotic, such as meropenem/vaborbactam, may be valuable therapeutic options." @default.
• W4366609072 created "2023-04-23" @default.
• W4366609072 creator A5008183147 @default.
• W4366609072 creator A5012179160 @default.
• W4366609072 creator A5013859383 @default.
• W4366609072 creator A5017330811 @default.
• W4366609072 creator A5025463372 @default.
• W4366609072 creator A5034324107 @default.
• W4366609072 creator A5039012036 @default.
• W4366609072 creator A5056284122 @default.
• W4366609072 creator A5068488687 @default.
• W4366609072 creator A5069915944 @default.
• W4366609072 creator A5075046548 @default.
• W4366609072 creator A5075372109 @default.
• W4366609072 creator A5087095630 @default.
• W4366609072 date "2023-06-01" @default.
• W4366609072 modified "2023-10-14" @default.
• W4366609072 title "Ceftazidime/avibactam-resistant meropenem-susceptible KPC-producing Klebsiella pneumoniae: Analysis of cases and evaluation of in vitro activity of fosfomycin-containing combinations" @default.
• W4366609072 cites W1977371637 @default.
• W4366609072 cites W2099249152 @default.
• W4366609072 cites W2339454548 @default.
• W4366609072 cites W2590149742 @default.
• W4366609072 cites W2591642302 @default.
• W4366609072 cites W2607050795 @default.
• W4366609072 cites W2725848895 @default.
• W4366609072 cites W2792380978 @default.
• W4366609072 cites W2807053173 @default.
• W4366609072 cites W2971823933 @default.
• W4366609072 cites W2982773974 @default.
• W4366609072 cites W2985478486 @default.
• W4366609072 cites W2995664785 @default.
• W4366609072 cites W3005470867 @default.
• W4366609072 cites W3007464332 @default.
• W4366609072 cites W3048457837 @default.
• W4366609072 cites W3091573243 @default.
• W4366609072 cites W3092391711 @default.
• W4366609072 cites W3110298378 @default.
• W4366609072 cites W3126898986 @default.
• W4366609072 cites W3133086699 @default.
• W4366609072 cites W3136599471 @default.
• W4366609072 cites W3137942377 @default.
• W4366609072 cites W3154167381 @default.
• W4366609072 cites W3158695052 @default.
• W4366609072 cites W3173720603 @default.
• W4366609072 cites W3181918036 @default.
• W4366609072 cites W3188173177 @default.
• W4366609072 cites W3198667590 @default.
• W4366609072 cites W3201048662 @default.
• W4366609072 cites W3215068065 @default.
• W4366609072 cites W4205103838 @default.
• W4366609072 cites W4210521318 @default.
• W4366609072 cites W4225937940 @default.
• W4366609072 cites W4282947322 @default.
• W4366609072 cites W4295185337 @default.
• W4366609072 cites W4303709748 @default.
• W4366609072 cites W4313576388 @default.
• W4366609072 doi "https://doi.org/10.1016/j.jgar.2023.03.012" @default.
• W4366609072 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37086891" @default.
• W4366609072 hasPublicationYear "2023" @default.
• W4366609072 type Work @default.
• W4366609072 citedByCount "2" @default.
• W4366609072 countsByYear W43666090722023 @default.
• W4366609072 crossrefType "journal-article" @default.
• W4366609072 hasAuthorship W4366609072A5008183147 @default.
• W4366609072 hasAuthorship W4366609072A5012179160 @default.
• W4366609072 hasAuthorship W4366609072A5013859383 @default.
• W4366609072 hasAuthorship W4366609072A5017330811 @default.
• W4366609072 hasAuthorship W4366609072A5025463372 @default.
• W4366609072 hasAuthorship W4366609072A5034324107 @default.
• W4366609072 hasAuthorship W4366609072A5039012036 @default.
• W4366609072 hasAuthorship W4366609072A5056284122 @default.
• W4366609072 hasAuthorship W4366609072A5068488687 @default.
• W4366609072 hasAuthorship W4366609072A5069915944 @default.
• W4366609072 hasAuthorship W4366609072A5075046548 @default.
• W4366609072 hasAuthorship W4366609072A5075372109 @default.
• W4366609072 hasAuthorship W4366609072A5087095630 @default.
• W4366609072 hasBestOaLocation W43666090721 @default.
• W4366609072 hasConcept C104317684 @default.
• W4366609072 hasConcept C176947019 @default.
• W4366609072 hasConcept C2775933652 @default.
• W4366609072 hasConcept C2776968632 @default.
• W4366609072 hasConcept C2777058267 @default.
• W4366609072 hasConcept C2777406300 @default.
• W4366609072 hasConcept C2777427914 @default.
• W4366609072 hasConcept C2777637488 @default.
• W4366609072 hasConcept C2778897966 @default.
• W4366609072 hasConcept C2779375183 @default.
• W4366609072 hasConcept C2780493024 @default.
• W4366609072 hasConcept C501593827 @default.
• W4366609072 hasConcept C523546767 @default.
• W4366609072 hasConcept C54355233 @default.
• W4366609072 hasConcept C547475151 @default.
• W4366609072 hasConcept C55493867 @default.
• W4366609072 hasConcept C71924100 @default.
• W4366609072 hasConcept C86803240 @default.
• W4366609072 hasConcept C89423630 @default.
• W4366609072 hasConcept C94665300 @default.
• W4366609072 hasConceptScore W4366609072C104317684 @default.

• next